Phase 2 Study of Erlotinib Versus Gefitinib in Advanced Non Small Cell Lung Cancer With exon21 Mutation.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
- 29 Jul 2013 Planned end date changed from 1 Jul 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.